Estimating minimally important differences for the worst pain rating of the brief pain inventory-short form

Journal of Supportive Oncology

Volumn 9, Issue 2, 2011, Pages 72-78

  Mathias, Susan D ^a,b,c   Crosby, Ross D ^a,b,c   Qian, Yi ^a,b,c   Jiang, Qi ^a,b,c   Dansey, Roger ^a,b,c   Chung, Karen ^a,b,c  

^a Health Outcomes Solutions   (United States)

^b NEUROPSYCHIATRIC RESEARCH INSTITUTE   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; ZOLEDRONIC ACID;

ADULT; AGED; ANCHOR BASED ANALYSIS; ARTICLE; BONE DISEASE; BONE METASTASIS; BREAST CANCER; BRIEF PAIN INVENTORY SHORT FORM; CONTROLLED STUDY; DISTRIBUTION BASED ANALYSIS; EFFECT SIZE; EUROQOL 5 DIMENSIONS; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY BREAST CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMALLY IMPORTANT DIFFERENCE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; SCORING SYSTEM; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; MIDDLE AGED; PAIN MEASUREMENT; RANK LIGAND;

EID: 80052466694     PISSN: 15446794     EISSN: 1879596X     Source Type: Journal    
DOI: 10.1016/j.suponc.2010.12.004     Document Type: Article

References (24)

1. Wyrwich K.W., Bullinger M., Aaronson N., et al. Estimating clinically significant differences in quality of life outcomes. Qual Life Res 2005, 14:285-295.
2. Mathias S.D., Gao S.K., Rutstein M., Snyder C.F., Wu A.W., Cella D. Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences. Curr Med Res Opin 2009, 25(2):375-383.
3. Yost K.J., Sorensen M.V., Hahn E.A., Glendenning G.A., Gnanasakthy A., Cella D. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. Value Health 2005, 8(2):117-127.
4. Hays R.D., Woolley J.M. The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it?. Pharmacoeconomics 2000, 18(5):419-423.
5. Daut R.L., Cleeland C.S., Flanery R.C. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983, 17(2):197-210.
6. Cleeland C. Brief Pain Inventory User Guide 2009, University of Texas M. D. Anderson Cancer Center, Houston.
7. Dworkin R.H., Turk D.C., Farrar J.T., et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005, 113(1-2):9-19.
8. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims 2009, U.S. Department of Health and Human Services Food and Drug Administration (FDA), FDA, Silver Spring, MD.
9. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5(6):649-655.
10. Brady M.J., Cella D.F., Mo F., Bonomi A.E., et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast Cancer Quality of Life instrument. J Clin Oncol 1997, 15:974-986.
11. Crosby R.D., Kolotkin R.L., Williams G.R. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003, 56(5):395-407.
12. Revicki D., Hays R.D., Cella D., Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008, 61(2):102-109.
13. Cella D., Hahn E.A., Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res 2002, 11(3):207-221.
14. Eton D.T., Cella D., Yost K.J., et al. A combination of distribution- and anchor-based approaches determined the minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004, 57:898-910.
15. Weibe S., Matijevic S., Eliasziw M., Derry P.A. Clinically important change in quality of life in epilepsy. J Neurol Neurosurg Psychiatry 2002, 73:116-120.
16. Miller K.L., Walt J.G., Mink D.R., et al. Minimal clinically important difference for the ocular surface disease index. Arch Ophthalmol 2010, 128(1):94-101.
17. Wyrwich K.W., Tierney W.M., Wolinsky F.D. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999, 52(9):861-873.
18. Wolinsky F.D., Wan G.J., Tierney W.M. Changes in the SF-36 in 12 months in a clinical sample of disadvantaged older adults. Med Care 1998, 36(11):1589-1598.
19. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Lawrence Erlbaum, Hillsdale, NJ. 2nd ed.
20. Guyatt G.H., Bombardier C., Tugwell P.X. Measuring disease-specific quality of life in clinical trials. CMAJ 1986, 134(8):889-895.
21. Norman G.R., Stratford P., Regehr G. Methodological problems in the retrospective computation of responsiveness to change: the lesson of Cronbach. J Clin Epidemiol 1997, 50(8):869-879.
22. Stopeck A., Body J., Fujiwara Y., et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. Eur J Cancer Suppl 2009, 7:2.
23. Pickard A.S., Neary M.P., Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007, 5:70.
24. Dworkin R.H., Turk D.C., Wyrwich K.W., et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008, 9(2):105-121.